Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) Free cash flow margin
Eli Lilly and Company's free cash flow margin over the twelve months to 30 June 2026 was 22.8%, up 9.1 percentage points from fiscal 2025 (13.8%). Over the past ten years it has ranged from 2.32% (fiscal 2023) to 22.7% (fiscal 2017); the current reading is higher than 36% of that period. That is above the Drug Manufacturers General industry median of 17.2% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 13.8% | 5.42 |
| FY2024 | 8.35% | 6.03 |
| FY2023 | 2.32% | (17.76) |
| FY2022 | 20.1% | (1.31) |
| FY2021 | 21.4% | 0.56 |
| FY2020 | 20.8% | 3.79 |
| FY2019 | 17.0% | (3.03) |
| FY2018 | 20.1% | (2.65) |
| FY2017 | 22.7% | 4.40 |
| FY2016 | 18.3% | 6.29 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 42.5% |
| ABBV AbbVie Inc. compare | 28.3% |
| NVS Novartis AG compare | 26.8% |
| AMGN Amgen Inc. compare | 26.7% |
| MRK Merck & Co., Inc. compare | 24.1% |
| LLY Eli Lilly and Company | 22.8% |
| PFE Pfizer Inc. compare | 17.3% |
| AZN AstraZeneca PLC compare | 10.2% |
| JNJ Johnson & Johnson compare | 0.00% |
| Drug Manufacturers General industry median | 17.2% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement